Multiple cycles of high-dose chemotherapy for ovarian cancer.
Recent advances in hematopoietic support have extended the application of high-dose chemotherapy in the treatment of malignancy. The use of colony-stimulating factors and peripheral blood progenitor cells significantly have decreased the morbidity and mortality of such treatment compared with traditional autologous bone marrow transplantation. These innovations facilitate the use of multiple cycles of high-dose chemotherapy as consolidation after achieving best response to conventional chemotherapy or as initial treatment. Developing data suggest that this approach in both of these settings merit further evaluation for the treatment of epithelial ovarian carcinoma.
Schilder
R J
RJ
Peripheral Stem Cell Program, Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA.
Shea
T C
TC
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D003115:Colony-Stimulating Factors / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D010051:Ovarian Neoplasms / Q000188:drug therapy*
D003115:Colony-Stimulating Factors